Key Takeaway: QIAGEN has launched the CE-IVDR certified QIAstat-Dx BCID GN Plus AMR Panel in Europe. This new diagnostic tool enhances the QIAstat-Dx platform's capabilities for detecting bloodstream infections. It targets 13 gram-negative bacterial pathogens and includes 18 antimicrobial resistance markers, providing comprehensive diagnostic options for healthcare providers.
Price reaction · baseline $41.56 (2026-07-14 close) · hit after-hours · 2 other QGEN headline(s) in the window, move may be shared
day 0 close · peak
-0.8%
Market Sentiment Analysis
POSITIVE FACTORS
Introduction of a new diagnostic panel for bloodstream infections.
CE-IVDR certification enhances credibility and market acceptance.
Broad coverage of gram-negative bacterial pathogens and AMR markers.
Full Press Release Details
VENLO, Niederlande & HILDEN, Deutschland--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Markteinführung des CE-IVDR-zertifizierten QIAstat-Dx BCID GN Plus AMR Panels bekannt gegeben. Damit bietet die QIAstat-Dx-Plattform in Europa nun ein umfassendes Angebot für die Diagnostik von Blutstrominfektionen. Das neue QIAstat-Dx BCID GN Plus AMR Panel weist 13 gramnegative bakterielle Zielpathogene und 18 Marker für antimikrobielle Resistenzen (AMR) aus positiv
Frequently Asked Questions
What is the QIAstat-Dx BCID GN Plus AMR Panel?
It is a new diagnostic panel for detecting bloodstream infections.
What pathogens does the QIAstat-Dx panel target?
It targets 13 gram-negative bacterial pathogens.
What certification does the new panel have?
The panel is CE-IVDR certified.
How many AMR markers are included in the panel?
The panel includes 18 antimicrobial resistance markers.